Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Rhea-AI Summary
Lexaria Bioscience (NASDAQ:LEXX) announced contracts with a CRO to run Animal Study #2 (GLP-1-A26-2) evaluating DehydraTECH formulations with next-generation GLP-1 drugs amycretin and retatrutide. The 18-arm study will measure 24-hour pharmacokinetics and tolerability, compare pills versus capsules, and test alternative enhancers such as sodium caprate. Dosing is expected within 30 days and the Study is fully funded from existing resources.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LEXX
On the day this news was published, LEXX declined 2.79%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.8% from its starting point during tracking. This price movement removed approximately $690K from the company's valuation, bringing the market cap to $24.04M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LEXX is up 2.19% while all three momentum-screened peers (ASBP, CRIS, SABS) are moving down, reinforcing that today’s move is stock-specific rather than a sector-wide GLP‑1 or biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | GLP-1 market outlook | Positive | -4.5% | Outlined rapid oral GLP‑1 pill growth and DehydraTECH opportunities. |
| Apr 15 | Preclinical study launch | Positive | +1.0% | Announced 2026 Animal Study #1 on DehydraTECH‑semaglutide and CBD. |
| Apr 07 | Peer drug approval | Positive | -6.6% | Applauded Eli Lilly’s oral GLP‑1 approval and highlighted prior data. |
| Apr 01 | Human GLP-1 trial | Positive | +11.0% | Detailed Human Pilot Study #7 comparing DehydraTECH-semaglutide to Wegovy. |
| Mar 26 | Patent portfolio growth | Positive | -3.1% | Announced five new patents across Japan and Australia for DehydraTECH. |
Recent GLP‑1 and IP announcements have often been followed by negative price reactions, with 3 divergences versus 2 alignments on generally positive news.
Over the past month, Lexaria has repeatedly highlighted its GLP‑1 franchise and DehydraTECH platform. News included expectations for large oral GLP‑1 pill market growth, new animal Study #1 contracts, and applauding Eli Lilly’s oral GLP‑1 approval. A human GLP‑1 clinical study announcement on Apr 1 coincided with an 11.04% gain, while other seemingly positive updates on patents and GLP‑1 demand saw negative reactions. Today’s new next‑generation GLP‑1 animal study extends this R&D and IP-building trajectory.
Market Pulse Summary
This announcement adds a sizable next‑generation GLP‑1 animal study with 18 arms, focusing on amycretin and retatrutide using DehydraTECH. It builds on recent GLP‑1 human and animal work and patent expansion while remaining fully funded from existing resources. Key aspects to watch include pharmacokinetic outcomes over the 24‑hour window, tolerability versus known GLP‑1 side effects, and how any results integrate with the company’s broader GLP‑1 and DehydraTECH development strategy.
Key Terms
glucagon-like peptide-1 medical
pharmacokinetic medical
salcaprozate sodium medical
sodium caprate medical
AI-generated analysis. Not financial advice.
Contracts signed for Animal Study #2: GLP-1-A26-2
Amycretin and retatrutide to be tested for compatibility with DehydraTECH
KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property claims.
Contracts with the CRO have been signed; Study design has been completed; formulation manufacturing is underway; and dosing is expected to begin within 30 days.
"The two most successful GLP-1 drugs on the market today are semaglutide and tirzepatide, accounting for more than
This is a large Study that will investigate 18 different study arms to evaluate new and novel DehydraTECH compositions. Blood samples will be taken at multiple timepoints through a 24-hour post-dosing period to quantify the pharmacokinetic ("PK") performance of each composition. The primary goals of this Study will be to investigate compatibility of amycretin and retatrutide with DehydraTECH formulation and processing technology, centered around PK performance and tolerability. Amycretin is owned by Novo Nordisk®, and retatrutide is owned by Eli Lilly and Company®.
As is the case with all GLP-1 drugs on the market today, common side effects of next-generation amycretin and retatrutide include nausea and gastrointestinal issues such as diarrhea and vomiting. With this Study and others, Lexaria will hope to establish that DehydraTECH processing of these drugs may lower the severity and instances of side effects.
This Study will also directly compare pill (tablet) formulations to capsules, to better understand the differences between absorption of the active drugs primarily through either the stomach (pills) or the intestine (capsules). Most oral GLP-1 drugs on the market today rely on pill formulations that are primarily absorbed through the stomach.
As in Animal Study #1 announced on April 15, this new Study will evaluate alternative formulations to salcaprozate sodium (SNAC) currently incorporated in Novo Nordisk's® oral Rybelsus® and Wegovy® tablet products. The present Study will include but not be limited to compositions using a different delivery enabling compound, sodium caprate, which has itself been shown to influence gastrointestinal absorption.
Lexaria will update its stakeholders once dosing has begun. The Study is fully funded from existing corporate resources.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire